Fig 1: Comparison of MDSCs, MDSC subsets, and MDSC effectors between the severe pneumonia subgroup and the non-severe pneumonia subgroup. (A) The percentages of MDSCs, CD11b+CD14-CD15+ LDG G-MDSCs and CD11b+CD14+HLA-DRlow/-CD15- M-MDSCs in PBMCs in the severe pneumonia subgroup (n = 18) and the non-severe pneumonia subgroup (n = 40). Tested by the Mann–Whitney U test. (B) MDSC effectors, such as Arg-1, S100A8/A9, and S100A12, in the severe pneumonia subgroup (n = 18) and the non-severe pneumonia subgroup (n = 40). Tested by the Mann–Whitney U test. MDSC, myeloid-derived suppressor cell; LDG, low-density granulocyte; G-MDSC, granulocytic-MDSC; M-MDSC, monocytic-MDSC; PBMCs, peripheral blood mononuclear cells; Arg-1, arginase-1.
Fig 2: Comparison of MDSCs, MDSC subsets, and MDSC effectors between the pneumonia group and the stable group. (A) The percentages of MDSCs, CD11b+CD14-CD15+ LDG G-MDSCs and CD11b+CD14+HLA-DRlow/-CD15- M-MDSCs in peripheral blood mononuclear cells (PBMCs) in the pneumonia group (n = 58) and the stable group (n = 29). Tested by the Mann–Whitney U test. (B) MDSC effectors, such as Arg-1, S100A8/A9 and S100A12, in the pneumonia group (n = 58) and the stable group (n = 14). Tested by the Mann–Whitney U test. For S100A12, the left Y axis represents the pneumonia group and the right Y axis represents the stable group. MDSC, myeloid-derived suppressor cell; LDG, low-density granulocyte; G-MDSC, granulocytic-MDSC; M-MDSC, monocytic-MDSC; PBMCs, peripheral blood mononuclear cells; Arg-1, arginase-1.
Fig 3: Serum EV-derived ARG 1 levels were higher in T2DM patients compared with non-T2DM patients. Serum EV-derived ARG 1 levels of T2DM group were higher than the non-T2DM group (104.99[90.05–126.10] vs. 40.50[12.67–68.05] pg/mL, p < 0.001). It showed the probability density of the data with different values on each side. EV Extracellular vesicles, T2DM Type 2 diabetes mellitus, ARG 1 Arginase 1. **p < 0.001
Supplier Page from Abcam for Human Arginase 1 ELISA Kit